The Effect of 8-week Dietary Intake of Novel Food Supplement on Minimal Erythema Dose

NCT ID: NCT06343610

Last Updated: 2025-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-15

Study Completion Date

2024-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a double-blind, randomized, placebo-controlled interventional study of the effect of multiple-dose dietary intake on minimal erythema dose and other skin parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-blind, randomized, placebo-controlled interventional study of the effect of multiple-dose dietary intake on minimal erythema dose and other skin parameters.

The study will be performed on 54 adults, between the ages 21 and 65 years and will include daily dietary supplementation over 8-weeks period.

Participants will be randomly assigned in one of two groups, 27 in each. One group (test group) will receive investigational product, a syrup containing red orange extract, Calaguala extract and vitamins A, C, D, E and the other placebo syrup. Participants will continuously receive placebo or investigational product for 8 weeks in order to determine multiple-dose effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Minimal Erythema Dose

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test group

Group Type ACTIVE_COMPARATOR

Active product

Intervention Type DIETARY_SUPPLEMENT

Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis; red orange extract), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.

Placebo group

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

No active ingredients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active product

Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis; red orange extract), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.

Intervention Type DIETARY_SUPPLEMENT

Placebo

No active ingredients.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Caucasian volunteers aged between 21 and 65 years at the time of the signature of Informed consent form (ICF),
* Signed Informed consent form (ICF),
* Fitzpatrick skin phototypes I-III,
* No skin pigmentation disorders,
* In good health condition,
* Willingness to avoid a consumption of any food supplements containing red orange extract, polypodium extract, carotenes or other antioxidants that could interfere with the results during the study,
* Willingness to avoid the sun, tanning beds and tanning products on the test area during the study,
* Willingness to follow all study procedures and keeping a diary during the study (to follow their compliance and palatability),
* No changes in dietary habits or dietary supplements in last 2 months prior to inclusion.
* No changes in cosmetic body care routine in last month prior to inclusion on measurement areas.
* No recent participation in any other similar study.
* No sun exposure (both natural and artificial) for at least two months before study start on the test area.
* Absence of sunburn, suntan, scars, or other active dermal lesions on the test area.
* Colour uniformity of the test area (without tattoo, nevi, blemishes or solar lentigo and without hair).

Exclusion Criteria

* Pregnancy or breastfeeding or planning pregnancy in next 6 months (for women)
* Known or suspected allergy to any ingredient of the tested products or UV radiation.
* Dermatological problems in the test area or the requirement for annual mole checks by a dermatologist.
* Pharmacological treatments (both locally or systemically) that could interfere with the results.
* Positive anamnesis for atopy (allergic hypersensitivity affecting parts of the body not in direct contact with the allergen)
* Use of self-tanning products for at least 2 months before study start.
* Medication with photosensitizing potential, drugs, corticoids in last month prior to study start.
* Regular consumption of food supplements containing red orange extract, polypodium extract, carotenoids or other antioxidants or supplements able to induce skin colour in last month before inclusion into the study.
* Any clinically significant history of melanoma or skin cancer (including their immediate family), serious metabolic disease, digestive tract disease, liver disease, kidney disease, haematological disease or other illness that could interfere with the study.
* History of severe reactions from exposure to sunlight (i.e., polymorphous light eruption)
* Any surgery, chemical or physical treatment on the experimental area within the 12 months prior to the study or foreseeing it for the duration of the study.
* Regular depilation of test area.
* Planning a hospitalization during the study.
* Impaired immune system due to autoimmune diseases, or use of immunosuppressive medication.
* Mental incapacity that precludes adequate understanding or cooperation.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VIST - Faculty of Applied Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VIST - Faculty of Applied Sciences, Institute of Cosmetics

Ljubljana, , Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovenia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VIST TO-UV 01-2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.